Intelligence · Essentials
Track the whole cannabis market. Without reading it.
Nobody can read every market. Essentials tracks all of them for you — every development vetted, classified and filed, the whole market written up once a month, and the datasets, trackers and analyst library underneath it. You stop chasing and start knowing.
Content HubNews DashboardM&A TrackerMonthly Brief
Analyst insights — with the data underneath
DatapackAustralia Market Datapack — the 2025 reset: record supply, a 40% price fall
Q1Q2Q3Q4Q1Q2
FlowerOilOther
SupplyrecordPrice−40%
Units dispensedrecord high▲Average unit price−40%▼Active prescribersstill climbing▲
Sources: TGA SAS-B · ODC import permits · operator disclosures
DatasetGermany: retail and wholesale cannabis pricing, 2023–2026
WebinarCannabinoid Pharma Comes of Age — full transcript and slide pack
DateCategoryMarket verticalCountry ▾Company
Canada ✓GermanyPortugal
CARegulationHealth Canada opens consultations on deregulating hemp★
CAMarketCanopy Growth Q1 FY2027: net revenue C$81.2M, up 13% YoY★
CAScienceSystematic review: CBD raises plasma availability of THC★
Deal volume by verticalCultivation 34%Pharma 27%Retail 22%Tech 17%
Deal count by countryCanadaUSAGermanyUKPortugal
Tilray → Lyphe GroupUK1.61M shares
Verano → Cannabist (AZ + VA)USUS$105M
Emblem → Ayurcann (assets)CAC$5.5M
July 2026 — what moved, market by market
🇺🇸USA🏛️ Regulation📈 Market🧪 Science
DEA Schedule III hearing opens; first plant-touching NYSE listings
🇩🇪Germany🏛️ Regulation📈 Market🧪 Science
Exilby wins Europe’s first cannabis-derived painkiller authorisation
🇧🇷Brazil🏛️ Regulation📈 Market🧪 Science
ANVISA widens formal access as domestic production starts
Every row carries its primary source.
What you get
Four layers of intelligence, one subscription.
Each answers a different question — what it means, what is underneath it, what happened, and how it compares.
🗞️judgementThe monthly briefWhat moved in every international market last month, written up one market at a time — with the call on what it means, not just what happened.🔎depthThe content hubAnalyst insights with the dataset, the reconciliation and the primary documents attached — plus every webinar, transcribed and analysed.🗂️recallThe news dashboardEvery development vetted, summarised and classified, so the archive still answers questions months after the headline has gone.📈structureThe trackersM&A, regulatory, market and science, each kept as a dataset you can filter — not a feed you have to read.
The monthly brief
Read the market when it lands, not a month later.
In the first week of every month, the brief lands: what moved in every international market, written up one at a time, with the call on what it means. It reaches the open web a month later — free to read, but by then the decisions it covers have already been taken.
Reading it free, today
June 2026
The newest edition on the open web. Two months behind the market it describes.
Reading it on Essentials, today
July 2026
Delivered in the first week of the month, while the decisions it covers are still live.
Five gates, 270–412 sources, every edition.
01Retrieve, and account for everythingEvery source in scope is pulled and logged, so nothing is missed by accident.
02Read the whole month before placing anythingNo market is written up until the full month is in view — that is what makes a ranking possible.
03Verify against the article, not the headlineEach claim is checked against the underlying piece, filing or dataset.
04Rank by what actually changedPlacement follows materiality, not volume of coverage.
05Then look again, independentlyA second sweep of every tier-1 and tier-2 source, run fresh.
What one market looks like inside it. A real entry — Germany, June 2026.
GermanyJune 2026 · Regulation
On the radarBundestag hearing on the GKV draft, and Exilby's September launch price.
Germany’s month is defined by a first, not the reimbursement fight — Exilby wins Europe’s first marketing authorisation for a cannabis-derived non-opioid painkiller.
🏛️RegulationExilby (VER-01) authorised 9 June — chronic radicular low-back pain, >1,200 Phase III patients, launch September 2026
📈MarketGKV draft, ref. 21/6130 §31(6) SGB V — would strip dried flower from statutory reimbursement — Bundestag hearing 22 June
🧪ScienceCannabis Act user survey, 11,471 users — legal sourcing rose 23.5% → 88.4% after the Act
On the radar, first
What is not yet decided opens the entry — you see it before it lands, not after.
A judgement, not a summary
The line under it says what the month actually meant for that market.
Three lenses, every market
Regulation, market and science — each with the primary document behind it.
Up to three key figures
Each with its date, its scale and the source it came from.
Every market written up — June 2026 edition
USAGermanyCanadaBrazilAustraliaThailandUKFranceNetherlandsIsraelPortugalUkrainePolandSpainArgentinaSwitzerlandNew ZealandIrelandEUItalySouth AfricaMoroccoUruguayGreeceCzech RepublicIndiaJapanLuxembourgCyprusMaltaSerbiaTaiwanNepalNew CaledoniaBahamasGhanaZimbabweZambiaNamibia
Thirty-nine that month. Between thirty and fifty in any given edition, each with its own judgement, figures and sources.
Proof
120+ markets, every story classified.
120+
markets
9,500+
classified news
490+
regulatory briefs
110+
analyst datapacks
Monthly
brief
Vetted from 420+ monitored sources and 780+ primary-source documents — every story classified by market and topic.
The content hub
The article is the summary. The hub is the evidence.
Every analyst insight in the hub carries the material the published version leaves out — the dataset it was built from, the reconciliation behind the headline figure, and the primary documents themselves. 124 sit there; 31 have been published openly.
Free article
In the hub
The chart
chart
→
interactive dashboard
The analysis
summary
→
full angle
The numbers
1headline figure
→
dataset + reconciliation
The sources
key links
→
full attribution + method
Webinars
Every session, transcribed and analysed for you.
Recorded with operators, clinicians and researchers working inside the markets we cover. You do not have to watch an hour of video: the full transcript is in the hub, already worked through, with the slide pack alongside it. 11 sessions sit there — the most recent below.
Portugal at a Crossroads: Boom, Bust, or Strategic Reset?Laura Ramos · CannaReporter / PTMC
Switzerland: on Track to Be Europe’s Next Cannabis Market of ScaleLuc Richner · Cannavigia
The Solventless Shift: Hash, Rosin & the Global Concentrate MapPeter Nel · GES Labs
Cannabinoid Pharma Comes of Age: What 1,305 Trials RevealGuillermo Moreno · Khiron
Inside the UK Medical Cannabis Market: from Emergence to ScaleMike Barnes · Medical Cannabis Clinicians Society
Beyond THC: Measuring What Matters in CannabisRubén Valenzuela · Valenveras
Czechia: Europe’s Cannabis FrontierLukas Hurt · Magazine Konopí
International Medical Cannabis Trade: 2025 recap, 2026 outlookDeepak Anand · ASDA ConsultingThe dashboard
Six ways into the same market. Pick one.
Roughly 520 developments were vetted, summarised and classified every month across the first half of 2026 — each with its primary source attached, and each filterable by date, category, market vertical, country and company.
Content Hub
Analyst insights, datapacks and webinar recaps — each with the data underneath it.
DatapackAustralia — the 2025 resetRecord supply against a 40% unit-price fall, with the quarterly series attached.
DatasetGermany pricing 2023–2026Retail and wholesale, three years, reconciled across sources.
TranscriptCannabinoid pharma, analysedThe full session transcript, already worked through, with the slide pack.
News Dashboard
Every classified development, filterable five ways.
DE · RegulationExilby authorisationEurope’s first authorisation for a cannabis-derived painkiller.
CA · MarketHigh Tide record revenueThe quarter that proved Canadian retail can be profitable at scale.
FR · ScienceU.Cannabis, 1,971 patientsThe largest patient cohort yet on cannabis and opioid reduction.
Regulatory
Laws, reforms, consultations and enforcement, market by market.
DEGKV draft would strip flower from reimbursementThe reimbursement fight that decides whether German flower stays funded.
AUTGA hardens advertising enforcementEnforcement, not rulemaking — the risk sits with how you advertise.
THHouse committee reviews relisting cannabisThe reversal that would put Thailand’s market back under prescription.
Market
Sales, imports, prescriptions, patients and company financials.
CAPre-rolls overtake flower at C$1.43bnFormat share moved before volume did — a leading indicator, not a lagging one.
UK2025 imports 30,061 kg; Canada supplies 70–80%Import dependence with a single dominant supplier is a concentration risk.
THCumulative exports 201,658 kgExport scale is now the argument for Thai supply, not domestic demand.
Science
Trials, studies, R&D and the evidence base.
FRU.Cannabis, 1,971 patients: opioid use fallsReal-world evidence at a scale regulators will actually read.
AUSydney RCT: high-dose CBD, pain 3.82 vs 4.36A controlled trial, so the effect size can be argued in a submission.
DECannabis Act survey, 11,471 usersLegal sourcing rose from 23.5% to 88.4% after the Act.
M&A Tracker
Deals, filings and consideration — who bought what, and for how much.
Tilray → LypheUK · 1.61M sharesVertical integration into UK prescribing, paid in stock.
Emblem → AyurcannCA · C$5.5MMulti-state consolidation continuing through the Schedule III window.
Verano → CannabistUS · US$105MAn asset purchase, not a going concern — the distinction matters.
Who uses it
Three jobs professionals hire Essentials to do.
Not a generic “who it’s for” — the questions you are actually trying to answer, and the part of the subscription that answers them.
Job 1
Stay current across every market
“What changed this month, and does it matter to me?”
The brief covers 30–50 countries individually. The dashboard holds every item behind them.
Who
Consultants · regulatory affairs · investors · independent analysts
Job 2
Build and defend a point of view
“What’s the real story behind the headline?”
124 insights with the dataset and the reconciliation attached, not just the narrative.
Who
Analysts · strategists · advisors · journalists
Job 3
Brief clients, teams and stakeholders
“How do I get other people up to speed, fast?”
A structured monthly read plus 11 recorded sessions with slide packs you can reuse.
Who
Business development · comms · founders · consultants
Questions
The things people ask before subscribing.
Three things. Timing — the monthly brief reaches you the day it ships, and only becomes public a month later. Depth — 124 insights in the content hub against 31 published openly, each with its underlying dataset, its reconciliation and its primary sources. And the dashboard itself: 9,500+ classified items you can filter by date, category, market vertical, country and company, plus 11 webinar recordings with their slide packs and the M&A tracker.
Each edition writes up 30 to 50 countries one at a time — 39 in June 2026, 52 in April. A country entry carries a thesis line, up to three key figures with the primary source attached, flags for regulation, business and science, and an “on the radar” note for what’s coming. There are 36 editions, going back to August 2023.
A newsletter is one editor’s pick and alerts are unfiltered noise. Essentials is vetted, summarised and classified by market and topic, with the primary source attached and the whole archive searchable months later — structure, not a stream.
Essentials keeps one professional current. Decide gives a team the connected, decision-grade view — every company, country, deal and filing cross-linked and reconciled. Track versus decide.
Continuously. Roughly 520 classified items were added each month across the first half of 2026, with the brief on top of that.
The last five editions covered between 30 and 52 countries each, deepest in the US, Germany, Canada, the UK and Australia. If your market is thin, say so — coverage moves with demand.
It is less than a couple of trade-press subscriptions, and it replaces hours of manual scanning every week. One regulation you didn’t miss pays for the year.
Pricing
A month of lead time, for less than a fortnightly coffee.
The brief in the first week of the month, and everything it is built on for the rest of it.
Essentials
€14.2/month
or €142 a year
The brief in the first week of every month · the content hub with its datasets · 11 analysed webinars · the news dashboard · the M&A tracker.
Start tracking →Self-serve checkout · cancel anytime
Need the connected, decision-grade view for a team? Decide →